REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2013 >

Decisions 9th April 2013

Recent JFG Decisions

 

At the meeting on the 9th April 2013 the following decisions / changes to the formulary were agreed:

 

New Drug Requests

  • No completed NDR were received for this meeting

 

New Drug Request - Appeal to decision

An appeal was lodged over the decision made on the 5th December 2012 to restrict the use of tolvaptan to Consultant endocrinologist for acutely ill patients with SIADH for 4 to 10 days as there was not sufficient Consultant endocrinologist cross cover for the acute patients within the oncology unit.

The JFG reconsidered the decision made and agreed to allow Consultant oncologists to use tolvaptan for acutely ill patients with SIADH for 4 to 10 days - TLS Red.

 

Specialised Commissioning

Cinryze®

  • Cinryze® to be added to formulary in accordance with NHS England Clinical Commissioning Policy: Treatment of Acute Attacks in Hereditary Angioedema which states the product with the lowest procurement cost should be used unless otherwise clinically indicated.